C5 (UK) will be holding its 21st Forum on Biotech Patenting on October 5-6, 2011 in London, England. In-house counsel, European and U.S. patent attorneys, and key regulators will provide information on:
• Best practices for obtaining approval for biosimilar products in Europe and the U.S.;
• The EPO factor: How the EPO's change in approach to biotech inventions will affect patenting strategies;
• New developments in the scope and patentability of gene sequence patents in Europe and the U.S. and what that means for patent portfolios;
• The latest update concerning the patentability of stem cells: EPO vs. ECJ;
• Proven strategies for overcoming complexities when filing successful antibody claims;
• Constructing functional claims that will withstand national court scrutiny;
• How case law developments relating to the patentability of second medical use will change the way patent applications are filed at the EPO; and
• Identifying opportunities and overcoming the challenges relating to small interfering ribonucleic acid (siRNA) molecules.
In particular, C5 faculty will offer presentations on the following topics:
• The U.S. biosimilars framework: Analysing the current approval requirements;
• How to successfully obtain regulatory approval for biosimilar products in light of recent European developments;
• The EPO factor: How the EPO's change in approach to biotech inventions will affect 2012 patenting strategies;
• How to navigate through antibody claims and personalised medicine/biomarkers in the U.S.;
• Analysing the current SPC landscape: Grant, scope and combination products;
• Exploring new developments in the scope and patentability of gene sequence patents;
• Determining the patentability of stem cells: EPO v. ECJ;
• Overcoming complexities to file successful antibody claims;
• Constructing functional claims that will withstand national court scrutiny;
• How case law developments relating to the patentability of second medical use claims will change the way patent applications are filed at the EPO;
• New initiatives by the EU on patent laws: 2011 developments and what to expect in the future?
• Identifying the opportunities and challenges of small interfering ribonucleic acid (siRNA) molecules;
• The impact of Myriad on the patentability of DNA sequences in the U.S.; and
• Capitalising on biotech patenting opportunities in China and India and strategies to overcome the common pitfalls.
Two additional pre-conference workshops will be offered on October 4, 2011. The first, entitled "Drafting Tips for Devising a Successful 'Global' Patent Application," will be held from 9:00 am to 12:00 pm, and the second, entitled "Constructing Effective Licensing Agreements to Capitalise on Current Market Opportunities" will be held from 1:00 pm to 4:00 pm.
The agenda for the Biotech Patenting conference can be found here (Day 1) and here (Day 2). A complete brochure for this conference, including an agenda, description of the sessions, list of speakers, and registration form can be downloaded here.
The registration fee for the conference is £1599, for the conference and one workshop £2199, and for the conference and both workshops £2499. Those registering by September 9, 2011 will receive a £100 discount. Those interested in registering for the conference can do so here, by calling +44 (0) 20 7878 6888, by faxing a registration form to +44 (0) 20 7878 6885, or by e-mailing [email protected].
Patent Docs is a media partner of C5's Biotech Patenting conference.
Comments